{"prompt": "['Table 3: EQD2values for HYPORT and a/B values for prostate, bladder, and', 'rectum', 'D (Gy)', 'd', 'a/B (Gy)', 'EQD2 (Gy)', '(Gy)', '1.5 (prostate', '62.5', '2.5', 'cancer)', '71', '62.5', '2.5', '3 (bladder)', '69', '62.5', '2.5', '5 (rectum)', '67', 'Abbreviations: HYPORT = hypofractionated post-prostatectomy radiotherapy;', 'D = total dose; d = fraction size; EQD2= equivalent dose in 2 Gy fractions', 'While there is dose escalation hypothesized for the rectum and bladder with', 'HYPORT compared to COPORT, radiobiologically equivalent rectal and bladder', 'treatment planning dose constraints will be used to safeguard against the risk of', 'greater rectal and/or bladder toxicity with HYPORT related to dose escalation.', '2.3', 'This trial is important because:', 'It is the only Phase III trial in the world exploring hypofractionation in the', 'postoperative arena.', 'It may redefine the standard of care to include HYPORT. The potential advantages of', 'HYPORT are:', 'Increase access for patients to postprostatectomy radiotherapy because of', 'fewer treatment days,', 'Increase convenience to patients because of fewer treatment days,', 'Reduced cost to patients because of fewer travel expenses and copays,', 'Improved resource utilization for physicians because fewer number of', 'treatments per patient and overall,', 'Reduced cost to society,', 'Increased RT utilization,', 'Improved efficacy of radiation treatment due to biological dose escalation.', '3. PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA', 'Note: Per NCI guidelines, exceptions to inclusion and exclusion criteria are not', 'permitted. For questions concerning eligibility, please contact the Biostatistical/Data', 'Management Center (via the contact list on the NRG web site). For radiation therapy-related', 'eligibility questions, please contact RTQA (via the contact list on the NRG web site).', '3.1', 'Patient Selection Guidelines', 'Although the guidelines provided below are not inclusion/exclusion criteria, investigators', 'NRG-GU003', '15', 'Version Date: April 26, 2019']['should consider these factors when selecting patients for this trial. Investigators also', 'should consider all other relevant factors (medical and non-medical), as well as the risks', 'and benefits of the study therapy, when deciding if a patient is an appropriate candidate', 'for this trial.', '3.1.1 Patients must have the psychological ability and general health that permits completion of', 'the study requirements and required follow up, including all quality of life surveys', 'through 5 years of follow-up.', '3.2', 'Eligibility Criteria', 'A patient cannot be considered eligible for this study unless ALL of the following', 'conditions are met.', 'Prior to Step 1 Registration', '3.2.1 Adenocarcinoma of the prostate treated primarily with radical prostatectomy.', 'Any type of radical prostatectomy will be permitted, including retropubic, perineal,', 'laparoscopic or robotically assisted. There is no time limit for the date of radical', 'prostatectomy.', '3.2.2 One of the following pathologic T-classifications: pT2 or pT3.', 'Patients with positive surgical margins are eligible.', '3.2.3', 'One of the following pathologic N-classifications: pNO, pNX.', 'If a lymph node dissection is performed, the number of lymph nodes removed per', 'side of the pelvis and the extent of the pelvic lymph node dissection (obturator vs.', 'extended lymph node dissection) should be noted whenever possible.', '3.2.4', 'No clinical evidence of regional lymph node metastasis.', 'CT (with contrast if renal function is acceptable; a noncontrast CT is permitted if', 'the patient is not a candidate for contrast), MRI, nodal sampling, or dissection of', 'the pelvis within 120 days prior to Step 1 registration.', 'Patients with pelvic lymph nodes equivocal or questionable by imaging are', 'eligible if the nodes are < 1 cm in the short axis.', '3.2.5 A post-radical prostatectomy study entry PSA >45 days after prostatectomy and within', '30 days prior to Step 1, < 2.0 ng/mL.', '3.2.6 No evidence of a local recurrence in the prostate fossa based on a digital rectal', 'examination (DRE) within 60 days prior to Step 1 registration.', 'Patients with equivocal or questionable DRE findings should have an MRI of the', 'pelvis to exclude the presence of a prostate fossa mass.', 'Patients with equivocal or questionable exam findings by DRE or MRI are', 'eligible if a biopsy of the lesion is negative for tumor.', '3.2.7', 'No evidence of bone metastases (M0) on bone scan (Na F PET/CT is an acceptable', 'substitute) within 120 days prior to Step 1 registration.', 'Equivocal bone scan findings are allowed if plain films and/or MRI are negative', 'for metastasis.', 'NRG-GU003', '16', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}